Skip to main content

Specialty Pharmacy

  • FDA approved 22 new drugs in lower-than-average 2016
    SILVER SPRING, Md. — The Food and Drug Administration’s Center for Drug Evaluation and Research’s number of new drug approvals came in low in 2016, according to the agency’s year-end review of the new therapies that passed regulatory muster. The number of drugs the FDA approved last year, 22, is less than half of the 45 approved in 2015 and lower than the average of the last 10 years of approvals, which is 29. 
     

  • OncoGenex to acquire Achieve Life Science

    BOTHEL, Wash., and VANCOUVER, British Columbia — OncoGenex Pharmaceuticals will acquire Achieve Life Science in all-stock transaction. OncoGenex is a publicly traded oncology biopharmaceutical company, while Achieve is a privately held specialty pharmaceutical provider.

    Under terms of the agreement, expected to close in mid-2017, Achieve’s shareholders will own 75 percent of the combined company, while OncoGenex shareholders will own the remaining 25 percent.

  • National Association of Specialty Pharmacy names new president and president-elect

    WASHINGTON, D.C. — The National Association of Specialty Pharmacy named Rebecca Shanahan president and Mike Agostino president-elect effective Jan. 1.

    Each served on the non-profit organization’s board of directors and executive committee. Shanahan, a 20-plus year industry veteran and CEO of Avella Specialty Pharmacy, is succeeding Burt Zweigenhaft in the role.

  • Forbes: Pharma innovation getting harder as approvals fall

  • FDA approves Clovis Oncology’s Rubraca

    WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Clovis Oncology’s Rubraca (rucaparib) for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar
    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • Obama signs 21st Century Cures Act
    WASHINGTON — President Barack Obama on Tuesday signed the 21st Century Cures Act into law in a ceremony at the White House, where he introduced by Vice President Joe Biden. The act, one of the last the outgoing president is expected to sign, will invest more than $6 billion over seven years to provide funding for various initiatives, including fighting prescription drug abuse, expanding the president’s Precision Medication Initiative and funding the “cancer moonshot,” aimed at finding new and better treatments for cancer. 
     

  • Diplomat named National Standard amid Michigan’s Top Workplaces
    FLINT, Mich. — The Detroit Free Press has recognized Diplomat Pharmacy as one a 2016 Top Workplaces National Standard, the company announced Thursday. 
     
    The results come from an employee survey administered by research firm WorkplaceDynamics. The survey measured such aspects of workplace culture as alignment, execution and connection. This is the third year in a row the company has made the Top Workplaces list, and its fourth overall, having received the recognition in 2012 as well. 
     
X
This ad will auto-close in 10 seconds